| Name | Title | Contact Details |
|---|---|---|
Angela Wang |
Chief Financial Officer | Profile |
Aligos Therapeutics is discovering and developing new classes of compounds that interact directly with disease causing molecules. These approaches are targeting viral nucleic acids and their encoded proteins, as well as oncogenes and their resultant proteins. The company is also pursuing novel therapeutic agents aimed at activation of the immune system to resolve diseases that cause significant morbidity and mortality.
Kurion creates technological solutions to minimize and stabilize nuclear and hazardous waste for safe, secure and permanent disposal. Kurion’s suite of waste separation, stabilization and robotic technologies are complemented by engineering and environmental services that together provide an execution platform to service the world’s largest nuclear and hazardous waste sites. Backed by venture capital firms Lux Capital, Firelake Capital and Acadia Woods Partners, the Kurion executive team employs a collective 150 years of industry experience managing nuclear and hazardous waste for commercial and government sites worldwide. Kurion is based in Irvine, Calif., and operates a technology development center at its radioactive materials licensed facility in Oak Ridge, Tenn.; a detritiation testing facility in Houston, Texas; two facilities in Richland, Wash., for non-radioactive demonstration testing, engineering and storage of mobile systems; and an office in Loveland, Colo. for engineering design and development.
Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team’s considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease-associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in over 150 peer reviewed publications and in 25 clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer’s disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer.
resTORbio, Inc. is a clinical stage company, developing medicines to treat aging-related diseases and conditions. resTORbio`s lead program targets the mechanistic target of rapamycin complex 1 (mTORC1) pathway to treat aging-related diseases and conditions. Initially, resTORbio is focused on developing medicines that address conditions caused by immunosenescence, the decline in immune function due to aging. resTORbio has initiated a Phase 2b trial for its lead product candidate, RTB101, evaluating its potential to reduce the incidence of respiratory tract infections (RTI) in elderly individuals at increased risk of RTI-related morbidity and mortality. resTORbio`s lead program is built upon two Phase 2a clinical studies demonstrating promising safety and efficacy results in almost 500 elderly individuals.
Omnicia is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.